00:00
Okay, still looking at the
Neuraminidase Inhibitors,
but we're going to
look at Zanamivir.
00:06
Now it ends in "VIR",
remember that's the
clue about viruses.
00:10
But look at the slide got a
great picture for you there.
00:14
I love that we've
shown you what it looks
like for this special
unique powder inhaler.
00:19
That's why I've got the,
besides shooting out there
because this one is available.
00:24
IVPO inhalation powder.
00:27
You can also take it as a
nebulizer or an intranasal.
00:30
So we've got a lot of
options for taking it
will talk about those
in just a minute
but here's good news for
really tired students.
00:39
Look at the common adverse
effects for both of these drugs.
00:42
Oseltamivir and
you've got Zanamivir
what's in common?
Yeah.
00:47
Look at these two lists.
00:49
This most common adverse
effects are the same
just about all the way
down, right?
So you don't have to
memorize these separately.
00:57
You chunk this
information together
and remind yourself
whether it's Tamiflu.
01:02
And what's the generic?
or it's relenza?
And what's the generic?
Right.
01:08
They have the most
common adverse effects
that most of your
patients will experience
are very similar.
01:15
Now, let's talk about the
more intense side effects
of the relenza.
01:19
You see we've got
that inhalation powder
got the name underneath it.
01:23
That's what it
kind of looks like.
01:24
It's a very unique unit
that you used for this
inhalation powder.
01:29
But think about
patients with lung risk.
01:32
So are talking about
an inhalation powder.
01:35
It would make sense.
01:36
It'll be easier for
you to remember.
01:38
Oh, somebody with lung problems.
01:40
This might be a problem.
01:42
So if they've got a potential
higher risk for patients
who have lung disease,
so if a patient who's asthmatic
think when they normally
inhale things in
I can be a little
problematic for them.
01:52
Now if it's a bronchodilator,
that's a good thing.
01:55
But if I taking
an inhaled powder
this might give us
some more problems.
01:59
So it could cause a bronchospasm
or some other
respiratory challenges
that would cause them
to have what we call
a respiratory decline
that just means they're breathing
is becoming more labored.
02:10
They're having problems.
02:11
They're not oxygenating as well.
02:14
That's what respiratory
decline would be.
02:16
So somebody with lung problems
takes these inhaled powders,
they might cause a bronchospasm
or respiratory decline.
02:23
Now some patients.
02:24
It's been kind of severe
like they needed
to be hospitalized
in order to recover
from from this.
02:29
But see here's the problem.
02:31
We're not really sure
if the effect of needing
to be hospitalized
was because of the
virus influenza virus
or using the powder inhaler,
but keep in mind somebody
who uses a powder inhaler.
02:45
Hey, there's some cool
things about that.
02:47
Maybe the patient has difficulty
swallowing pills yours.
02:50
Not gonna have to be IV.
02:52
And another cool thing
this is delivering
the medication
right to the site
of the problem.
02:58
That's usually our
preferred route
because the more medication we
can get right to the target,
That's awesome for
lots of reasons.
03:06
I get the medication
to where it's needed.
03:09
You have less
systemic side effects,
but if I already
have sensitive lungs,
this could be problematic.
03:15
So we spent time on this
just to help you keep in mind
that this is an influenza
infecting F impacting
the respiratory system.
03:26
It's really cool to
deliver a medication
right to this part
of the problem.
03:31
However, if they have
difficulties with lungs already,
this might not be the
best choice to deliver it
with this route.
03:38
So strongly consider
another route
if it's problematic
for a patient
to have an inhale
route like this.
03:45
Okay, let's look at peramivir,
again it ends in "VIR",
so we know that it goes right?
right against that virus,
now this is an IV one
so we don't see a
lot of these given,
in an outpatient typesetting
and patients must be greater
than 6 months of age.
04:01
We gave one dose over
30 to 60 minutes.
04:04
So technically
this could be given
right in an ER.
04:08
Now adverse effects
most commonly,
It's the GI effects.
04:11
I know we're giving it IV,
but they can still end
up with some kind of
irritable GI stuff
and up with diarrhea.
04:18
Now this is also rare
that they'd have a
hypersensitivity disorder,
but it is a possibility.
04:23
Again common theme
with with all these antivirals
that we've discussed so far.